[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622669":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":42,"centralContacts":46,"locations":57,"responsibleParty":76,"collaborators":51,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":51,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":51,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":51,"overallStatus":60,"whyStopped":51,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"sufentanil group","ACTIVE_COMPARATOR","Administer 0.15 μg\u002Fkg (maximum 10 μg) of sufentanil intravenously 40 minutes before the end of surgery, followed by the connection of a sufentanil patient-controlled intravenous analgesia (PCIA). Analgesic pump formula: Sufentanil 150 μg + 0.9% normal saline, total volume 150 mL (containing sufentanil 1 μg\u002FmL). PCIA settings: Single loading dose 1 mL (containing sufentanil 1 μg), lockout interval 10 min, background infusion 1 mL\u002Fh.",[13,14],"Procedure: Intercostal Nerve Block","Drug: Sufentanil",{"label":16,"type":17,"description":18,"interventionNames":19},"Tegileridine group","EXPERIMENTAL","Administer 0.015 mg\u002Fkg (maximum 1mg) of tegileridine intravenously 40 minutes before the end of surgery, followed by the connection of a tegileridine patient-controlled intravenous analgesia (PCIA). Analgesic pump formula: Tigrilidine 15,000 μg + 0.9% normal saline, total volume 150 mL (containing Tigrilidine 100 μg\u002FmL). PCIA settings: Single loading dose 1 mL (containing Tigrilidine 100 μg), lockout interval 10 min, background infusion 1 mL\u002Fh.",[20,13],"Drug: Tegileridine",[22,29,36],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Tegileridine","Administer 0.015 mg\u002Fkg (maximum 1mg) of tegileridine intravenously 40 minutes before the end of surgery, followed by the connection of a tegileridine patient-controlled intravenous analgesia (PCIA)",[16],[28],"Tegi",{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"PROCEDURE","Intercostal Nerve Block","Before closing the chest, the thoracic surgeon injected 3mL of 0.4% ropivacaine into the 4th, 5th, 6th and 7th intercostal spaces through thoracoscopy for intercostal nerve block.",[16,9],[35],"ICNB",{"type":23,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Sufentanil","Administer 0.15 μg\u002Fkg (maximum 10 μg) of sufentanil intravenously 40 minutes before the end of surgery, followed by the connection of a sufentanil patient-controlled intravenous analgesia (PCIA)",[9],[41],"Sufen",[43],{"name":44,"affiliation":5,"role":45},"aihua Du, Dr.","STUDY_CHAIR",[47,53],{"name":48,"role":49,"phone":50,"phoneExt":51,"email":52},"Aijun Xu, Dr.","CONTACT","18627784217",null,"ajxu@tjh.tjmu.edu.cn",{"name":54,"role":49,"phone":55,"phoneExt":51,"email":56},"Hongbo Zheng, Dr.","02783663173","70663307@qq.com",[58],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Tongji hospital","RECRUITING","Wuhan","Hubei","430030","China","CN",{"type":67,"coordinates":68},"Point",[69,70],114.26667,30.58333,{"lat":70,"lon":69},[73,74],{"name":48,"role":49,"phone":50,"phoneExt":51,"email":52},{"name":44,"role":49,"phone":75,"phoneExt":51,"email":56},"02783663625",{"type":77,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":51,"oldOrganization":51},"PRINCIPAL_INVESTIGATOR","aijun xu","Clinical Professor","100622669","tegileridine-combined-with-intercostal-nerve-block-after-thoracoscopic-lung-resection-100622669",false,"NCT07386626","Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection","Study on the Analgesic Effect of Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection","Inclusion Criteria:\n\n* Age range: 18 to 75 years old;\n* Patients undergoing elective thoracoscopic lobectomy or segmentectomy;\n* ASA classification levels I-III;\n* BMI 18 \\~ 30 kg\u002Fm2。\n* Voluntarily participate and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with preoperative alcohol dependence and long-term use of analgesic drugs are receiving analgesic treatment for other acute and chronic pain;\n* Pregnant or lactating women;\n* Allergies or other contraindications to the anesthetics, analgesics, and antiemetic drugs used in the study;\n* Patients with severe sleep apnea syndrome or acute or severe bronchial asthma;\n* Suffering from mental and neurological disorders or cognitive impairment, known or suspected gastrointestinal obstruction, severe liver and kidney dysfunction (Child Pugh score C), chronic obstructive pulmonary disease or severe cardiovascular disease, etc;\n* Researchers consider participants who are not suitable to participate in this study and those who refuse to participate.","ALL","18 Years","75 Years",{"count":91,"type":92},118,"ESTIMATED","INTERVENTIONAL",[95],"NA","Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. Thus potentially achieving the analgesic goal of \"early pain relief, stable throughout the process, and rapid recovery,\" and may have a positive impact on reducing CPSP.",[98],"Lobectomy","2026-04-02",{"date":101,"type":102},"2026-04-08","ACTUAL",{"date":104,"type":102},"2026-03-18",{"date":106,"type":92},"2027-01-31",{"name":5,"class":6},1]